Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.

Parent Announcements (For Unsolicited or Investigator-Initiated Applications)

Parent announcements are broad funding opportunities that applicants can use to submit investigator-initiated applications for a range of popular programs. These announcements do not specify any particular area of scientific interest. They simply provide the standard forms and instructions needed to apply. Parent announcements are open for up to three years and are typically reissued to ensure continuity. They use standard due dates with three application, review, and award cycles each year.

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Sort descending Program Official
Biology of Bladder Cancer PAR-25-129 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 09/08/2025 Howard L. Parnes, M.D.
Notice of Special Interest (NOSI): Targeting the Endocannabinoid System for Brain Health and Acute and Chronic Diseases NOT-DA-22-048 01/08/2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes PAR-23-255 (R21 Clinical Trials Not Allowed) R21 09/08/2026 Wendy Wang, Ph.D., M.Sc.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes PAR-25-095 (R01 Clinical Trial Not Allowed) R01 Clinical Trial Not Allowed 09/08/2026 Wendy Wang, Ph.D., M.Sc.
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-286 (K99/R00 - Independent Clinical Trial Not Allowed) R00, K99 Clinical Trial Not Allowed 10/15/2026
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-287 (K99/R00 - Independent Clinical Trial Required) R00, K99 Clinical Trial Required 10/15/2026
NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required) R00, K99 10/15/2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-25-074 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/15/2026 Sudhir Srivastava, Ph.D., M.P.H.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-25-075 (UH3 Clinical Trials Not Allowed) UH3 10/15/2026 Sudhir Srivastava, Ph.D., M.P.H.
Notice of Special Interest (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research NOT-CA-24-074 01/08/2027 Nancy J. Emenaker, Ph.D., RDN, LD, FAND